FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3196356517> ?p ?o ?g. }

• W3196356517 endingPage "1675" @default.
• W3196356517 startingPage "1663" @default.
• W3196356517 abstract "Background: Istradefylline is a selective adenosine A2A receptor antagonist for the treatment of patients with Parkinson’s disease (PD) experiencing OFF episodes while on levodopa/decarboxylase inhibitor. Objective: This pooled analysis of eight randomized, placebo-controlled, double-blind phase 2b/3 studies evaluated the efficacy and safety of istradefylline. Methods: Istradefylline was evaluated in PD patients receiving levodopa with carbidopa/benserazide and experiencing motor fluctuations. Eight 12- or 16-week trials were conducted (n = 3,245); four of these studies were the basis for istradefylline’s FDA approval. Change in OFF time as assessed in patient-completed 24-h PD diaries at Week 12 was the primary endpoint. All studies were designed with common methodology, thereby permitting pooling of data. Pooled analysis results from once-daily oral istradefylline (20 and 40 mg/day) and placebo were evaluated using a mixed-model repeated-measures approach including study as a factor. Results: Among 2,719 patients (placebo, n = 992; 20 mg/day, n = 848; 40 mg/day, n = 879), OFF hours/day were reduced at Week 12 at istradefylline dosages of 20 mg/day (least-squares mean difference [LSMD] from placebo in reduction from baseline [95%CI], –0.38 h [–0.61, –0.15]) and 40 mg/day (–0.45 h [–0.68, –0.22], p < 0.0001); ON time without troublesome dyskinesia (ON-WoTD) significantly increased. Similar results were found in the four-study pool (OFF hours/day, 20 mg/day, –0.75 h [–1.10, –0.40]; 40 mg/day, –0.82 h [–1.17, –0.47]). Istradefylline was generally well-tolerated; the average study completion rate among istradefylline-treated patients across all studies was 89.2%. Dyskinesia was the most frequent adverse event (placebo, 9.6%; 20 mg/day, 16.1%; 40 mg/day, 17.7%). Conclusion: In this pooled analysis, istradefylline significantly improved OFF time and ON-WoTD relative to placebo and was well-tolerated." @default.
• W3196356517 created "2021-09-13" @default.
• W3196356517 creator A5001292694 @default.
• W3196356517 creator A5014705038 @default.
• W3196356517 creator A5017122855 @default.
• W3196356517 creator A5031345514 @default.
• W3196356517 creator A5044022978 @default.
• W3196356517 creator A5054027214 @default.
• W3196356517 creator A5057518385 @default.
• W3196356517 creator A5058511712 @default.
• W3196356517 creator A5060664922 @default.
• W3196356517 creator A5077163812 @default.
• W3196356517 creator A5080057970 @default.
• W3196356517 creator A5082659140 @default.
• W3196356517 date "2021-10-12" @default.
• W3196356517 modified "2023-10-14" @default.
• W3196356517 title "Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials" @default.
• W3196356517 cites W1493115321 @default.
• W3196356517 cites W1951726957 @default.
• W3196356517 cites W1970073512 @default.
• W3196356517 cites W1973335238 @default.
• W3196356517 cites W1974463013 @default.
• W3196356517 cites W1990269363 @default.
• W3196356517 cites W1997945197 @default.
• W3196356517 cites W2007390314 @default.
• W3196356517 cites W2014583561 @default.
• W3196356517 cites W2028129201 @default.
• W3196356517 cites W2035942308 @default.
• W3196356517 cites W2038310981 @default.
• W3196356517 cites W2042833008 @default.
• W3196356517 cites W2052889020 @default.
• W3196356517 cites W2070912312 @default.
• W3196356517 cites W2088277236 @default.
• W3196356517 cites W2108299953 @default.
• W3196356517 cites W2115639304 @default.
• W3196356517 cites W2142803792 @default.
• W3196356517 cites W2146659986 @default.
• W3196356517 cites W2193789687 @default.
• W3196356517 cites W2344408149 @default.
• W3196356517 cites W2401627386 @default.
• W3196356517 cites W2773325524 @default.
• W3196356517 cites W2775013655 @default.
• W3196356517 cites W2895194501 @default.
• W3196356517 cites W3033371162 @default.
• W3196356517 doi "https://doi.org/10.3233/jpd-212672" @default.
• W3196356517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34486986" @default.
• W3196356517 hasPublicationYear "2021" @default.
• W3196356517 type Work @default.
• W3196356517 sameAs 3196356517 @default.
• W3196356517 citedByCount "15" @default.
• W3196356517 countsByYear W31963565172022 @default.
• W3196356517 countsByYear W31963565172023 @default.
• W3196356517 crossrefType "journal-article" @default.
• W3196356517 hasAuthorship W3196356517A5001292694 @default.
• W3196356517 hasAuthorship W3196356517A5014705038 @default.
• W3196356517 hasAuthorship W3196356517A5017122855 @default.
• W3196356517 hasAuthorship W3196356517A5031345514 @default.
• W3196356517 hasAuthorship W3196356517A5044022978 @default.
• W3196356517 hasAuthorship W3196356517A5054027214 @default.
• W3196356517 hasAuthorship W3196356517A5057518385 @default.
• W3196356517 hasAuthorship W3196356517A5058511712 @default.
• W3196356517 hasAuthorship W3196356517A5060664922 @default.
• W3196356517 hasAuthorship W3196356517A5077163812 @default.
• W3196356517 hasAuthorship W3196356517A5080057970 @default.
• W3196356517 hasAuthorship W3196356517A5082659140 @default.
• W3196356517 hasBestOaLocation W31963565171 @default.
• W3196356517 hasConcept C126322002 @default.
• W3196356517 hasConcept C142724271 @default.
• W3196356517 hasConcept C168563851 @default.
• W3196356517 hasConcept C204787440 @default.
• W3196356517 hasConcept C27081682 @default.
• W3196356517 hasConcept C2779026782 @default.
• W3196356517 hasConcept C2779134260 @default.
• W3196356517 hasConcept C2779734285 @default.
• W3196356517 hasConcept C2780304432 @default.
• W3196356517 hasConcept C2780405171 @default.
• W3196356517 hasConcept C42219234 @default.
• W3196356517 hasConcept C71924100 @default.
• W3196356517 hasConceptScore W3196356517C126322002 @default.
• W3196356517 hasConceptScore W3196356517C142724271 @default.
• W3196356517 hasConceptScore W3196356517C168563851 @default.
• W3196356517 hasConceptScore W3196356517C204787440 @default.
• W3196356517 hasConceptScore W3196356517C27081682 @default.
• W3196356517 hasConceptScore W3196356517C2779026782 @default.
• W3196356517 hasConceptScore W3196356517C2779134260 @default.
• W3196356517 hasConceptScore W3196356517C2779734285 @default.
• W3196356517 hasConceptScore W3196356517C2780304432 @default.
• W3196356517 hasConceptScore W3196356517C2780405171 @default.
• W3196356517 hasConceptScore W3196356517C42219234 @default.
• W3196356517 hasConceptScore W3196356517C71924100 @default.
• W3196356517 hasIssue "4" @default.
• W3196356517 hasLocation W31963565171 @default.
• W3196356517 hasLocation W31963565172 @default.
• W3196356517 hasLocation W31963565173 @default.
• W3196356517 hasOpenAccess W3196356517 @default.
• W3196356517 hasPrimaryLocation W31963565171 @default.
• W3196356517 hasRelatedWork W1986916753 @default.
• W3196356517 hasRelatedWork W1998575521 @default.

• next